🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "major milestone" in the battle against drug-resistant strains of the bacteria, according to researchers.

A Global Public Health Issue

The sexually transmitted infection are escalating worldwide, with data suggesting more than 82 million infections annually. Notably increased rates are observed in the African continent and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an important and timely step in the reality of rising global incidence, the spread of superbugs and the highly restricted therapeutic options at this time.”

Medical experts are increasingly worried about the surge in drug-resistant strains. The World Health Organization has designated it as a "critical concern". Ongoing monitoring found that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Receive Authorization

Zoliflodacin, also known as Nuzolvence, was cleared by the US FDA in recent days for use against gonorrhoea. This disease can lead to significant complications, including infertility. Researchers believe that focused deployment of this new drug will help hinder the development of resistance.

Gepotidacin, developed by the drugmaker GSK, also received approval in the same week. This treatment, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to develop it.

“This approval signifies a significant shift in the therapy of highly resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Clinical Trial Outcomes and Worldwide Availability

According to data detailed in a prominent scientific publication, the new drug eradicated over nine in ten of uncomplicated infections. This puts it on an similar efficacy with the typical regimen, which combines a dual-drug approach. The study enrolled over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the authority to register and commercialise the drug in numerous low-income and middle-income countries.

Doctors on the front lines have voiced optimism. The availability of a single-dose, oral treatment such as this is seen as a "revolutionary step" for managing the epidemic. This is viewed as crucial to reduce the burden of the disease for people and to halt the transmission of extremely resistant gonorrhoea globally.